Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Distribution and cardiac outcomes of neuromuscular disorders referred to an inherited cardiac disease unit

View through CrossRef
Abstract Backgroud Neuromuscular disorders may present with varied cardiac involvement, including myocardial and conduction tissue disease. Sudden death is a common adverse event of cardiomyopathy Purpose The objective was to present clinical characteristics of neuromuscular disorders referred to a dedicated inherited cardiac disease unit with special interest in the mode of presentation, clinical course and cardiac complications. Methods Cardiological anamnesis, 12-lead electrocardiogram and bidimensional echocardiogram were performed to every individual. Gadolinium cardiac MRI/24 hour-Holter/coronariography were performed in particular cases where results of previous tests made it mandatory. Results 199 patients (aged 43.1±18.1 years, 45.2% females, 54.8% males) with neurological disorders evaluated in an inherited cardiac disease clinic from 2003–2021 were included. There were 20 (10.1%) dystrophynopathies, 20 (10.1%) limb girdle muscular dystrophy, 14 (7.0%) other muscular dystrophies (Emery-Dreifuss, facio-scapulo-humeral, oculopharyngeal), 70 (35.2%) myotonic myopathies (Steinert myotonic dystrophy, Becker myotonia congenita, Thomsen myotonia congenita), 7 (3.5%) myofibrillar myopathies, 14 (7.0%) congenital myopathies, 18 (9.0%) metabolic myopathies, 12 (6.0%) unknown origin inherited myopathies, 24 (12.1%) non-myopathic neurological diseases. There were 44 (22.11%) patients affected with a cardiomyopathy. 51/199 (25.6%) had conduction disturbances. 33/51 had pathological cardiac findings without clinical cardiomyopathy. Age of diagnosis of neurological and cardiomyopathy conditions were 28.4±20.4 and 40.6±18.4 years old respectively. Reasons for diagnosis were symptoms (164, 82.4%), family screening (27, 13.6%), incidental finding (7, 3.5%), sudden death (1, 0.5%). 31 (15.6%) had atrial fibrillation, 17 (8.5%) required pacemaker and 15 (7.5%) ICD implantation. 32 (16.1%) patients died or had severe cardiac outcome. 7 (3.5%) had sudden death or equivalent, 3 (1.5%) heart-failure-death, 1 (0.5%) received cardiac transplantation, 18 (9.1%) had other-disease-related-death and 3 (1.5%) other disease non-cadiac-related-death). Conclusion Neuromuscular diseases require periodic cardiac evaluation. Despite onset of neurological symptoms usually precede cardiac involvement, the burden of cardiac involvement and complications is highly significant. Cause of death in neurological conditions with cardiac involvement is mostly driven by the severity of the cardiomyopathy. Funding Acknowledgement Type of funding sources: None.
Title: Distribution and cardiac outcomes of neuromuscular disorders referred to an inherited cardiac disease unit
Description:
Abstract Backgroud Neuromuscular disorders may present with varied cardiac involvement, including myocardial and conduction tissue disease.
Sudden death is a common adverse event of cardiomyopathy Purpose The objective was to present clinical characteristics of neuromuscular disorders referred to a dedicated inherited cardiac disease unit with special interest in the mode of presentation, clinical course and cardiac complications.
Methods Cardiological anamnesis, 12-lead electrocardiogram and bidimensional echocardiogram were performed to every individual.
Gadolinium cardiac MRI/24 hour-Holter/coronariography were performed in particular cases where results of previous tests made it mandatory.
Results 199 patients (aged 43.
1±18.
1 years, 45.
2% females, 54.
8% males) with neurological disorders evaluated in an inherited cardiac disease clinic from 2003–2021 were included.
There were 20 (10.
1%) dystrophynopathies, 20 (10.
1%) limb girdle muscular dystrophy, 14 (7.
0%) other muscular dystrophies (Emery-Dreifuss, facio-scapulo-humeral, oculopharyngeal), 70 (35.
2%) myotonic myopathies (Steinert myotonic dystrophy, Becker myotonia congenita, Thomsen myotonia congenita), 7 (3.
5%) myofibrillar myopathies, 14 (7.
0%) congenital myopathies, 18 (9.
0%) metabolic myopathies, 12 (6.
0%) unknown origin inherited myopathies, 24 (12.
1%) non-myopathic neurological diseases.
There were 44 (22.
11%) patients affected with a cardiomyopathy.
51/199 (25.
6%) had conduction disturbances.
33/51 had pathological cardiac findings without clinical cardiomyopathy.
Age of diagnosis of neurological and cardiomyopathy conditions were 28.
4±20.
4 and 40.
6±18.
4 years old respectively.
Reasons for diagnosis were symptoms (164, 82.
4%), family screening (27, 13.
6%), incidental finding (7, 3.
5%), sudden death (1, 0.
5%).
31 (15.
6%) had atrial fibrillation, 17 (8.
5%) required pacemaker and 15 (7.
5%) ICD implantation.
32 (16.
1%) patients died or had severe cardiac outcome.
7 (3.
5%) had sudden death or equivalent, 3 (1.
5%) heart-failure-death, 1 (0.
5%) received cardiac transplantation, 18 (9.
1%) had other-disease-related-death and 3 (1.
5%) other disease non-cadiac-related-death).
Conclusion Neuromuscular diseases require periodic cardiac evaluation.
Despite onset of neurological symptoms usually precede cardiac involvement, the burden of cardiac involvement and complications is highly significant.
Cause of death in neurological conditions with cardiac involvement is mostly driven by the severity of the cardiomyopathy.
Funding Acknowledgement Type of funding sources: None.

Related Results

Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Deep Neuromuscular Blockade During General Anesthesia: Advantages, Challenges, and Future Directions
Deep Neuromuscular Blockade During General Anesthesia: Advantages, Challenges, and Future Directions
Background: Neuromuscular blocking agents play an important role in modern anesthesia by facilitating optimal surgical conditions through deep muscle relaxation. Additionally, neur...
Neuromuscular Blockers and Reversal Agents
Neuromuscular Blockers and Reversal Agents
Neuromuscular blocking drugs, which include depolarizing and nondepolarizing drugs, are used to facilitate intubation and provide skeletal muscle relaxation during surgery and in t...
THE IMPORTANCE OF SUGAMMADEX AT POSTOPERATIVE RESIDUAL NEUROMUSCULAR BLOCK
THE IMPORTANCE OF SUGAMMADEX AT POSTOPERATIVE RESIDUAL NEUROMUSCULAR BLOCK
Introduction: postoperative residual neuromuscular blockade is the postoperative muscle paralysis caused by incomplete or null antagonism of neuromuscular blocking agents. Post-sur...
Incidence of Venous Thromboembolism in Patients with Different Classes of Obesity in Comparison to Inherited Thrombophilias
Incidence of Venous Thromboembolism in Patients with Different Classes of Obesity in Comparison to Inherited Thrombophilias
Introduction: Obesity is a significant risk factor for venous thromboembolism (VTE). It is linked to physical inactivity, increased intra-abdominal pressure, chronic inflammation, ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...

Back to Top